Loading...
•
Sep 30, 2022
Sage Q3 2022 Earnings Report
Sage Therapeutics reported third quarter 2022 financial results and highlighted pipeline and business progress.
Key Takeaways
Sage Therapeutics reported $1.7 million in net revenue from sales of ZULRESSO in the third quarter of 2022. The company's cash, cash equivalents, and marketable securities totaled $1.4 billion as of September 30, 2022, and anticipates operations will be supported into 2025.
Completed rolling NDA submission for zuranolone in MDD and PPD is on track for December 2022.
Presented additional data across pipeline programs at key medical congresses including data on zuranolone as an investigational oral, once-daily, 14-day treatment for MDD and PPD.
Appointed Laura Gault, M.D., Ph.D., as Chief Medical Officer.
Cash and cash equivalents, anticipated funding from ongoing collaborations, and potential revenue, are expected to support operations into 2025.
Forward Guidance
Sage anticipates cash, cash equivalents and marketable securities of approximately $1.3 billion at the end of 2022. The Company anticipates R&D and SG&A spending to increase as it advances planned and ongoing studies for SAGE-718 and SAGE-324 and prepares for the potential launch of zuranolone. The Company believes its cash and cash equivalents, anticipated funding from ongoing collaborations, and potential revenue, will support its operations into 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...